HER2 is a member of the epidermal growth factor receptor family that occurs in about one-third of all breast cancers [2]; importantly, HER2 amplification causes aggressive cancer phenotype and poor clinical outcome [3,4]. This evidence concerns the gene ERBB2 and breast cancer.